- Home
- NGNE vs LOCO Comparison
NGNE vs LOCO Comparison
Compare NGNE & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- LOCO
- Stock Information
- Founded
- NGNE 2003
- LOCO 1980
- Country
- NGNE United States
- LOCO United States
- Employees
- NGNE N/A
- LOCO N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- LOCO Restaurants
- Sector
- NGNE Health Care
- LOCO Consumer Discretionary
- Exchange
- NGNE Nasdaq
- LOCO Nasdaq
- Market Cap
- NGNE 325.3M
- LOCO 323.7M
- IPO Year
- NGNE N/A
- LOCO 2014
- Fundamental
- Price
- NGNE $18.48
- LOCO $10.63
- Analyst Decision
- NGNE Strong Buy
- LOCO Buy
- Analyst Count
- NGNE 7
- LOCO 2
- Target Price
- NGNE $41.86
- LOCO $18.00
- AVG Volume (30 Days)
- NGNE 108.3K
- LOCO 168.4K
- Earning Date
- NGNE 08-11-2025
- LOCO 07-31-2025
- Dividend Yield
- NGNE N/A
- LOCO N/A
- EPS Growth
- NGNE N/A
- LOCO N/A
- EPS
- NGNE N/A
- LOCO 0.85
- Revenue
- NGNE N/A
- LOCO $479,690,000.00
- Revenue This Year
- NGNE N/A
- LOCO $6.29
- Revenue Next Year
- NGNE N/A
- LOCO $1.56
- P/E Ratio
- NGNE N/A
- LOCO $12.61
- Revenue Growth
- NGNE N/A
- LOCO 1.85
- 52 Week Low
- NGNE $6.88
- LOCO $8.29
- 52 Week High
- NGNE $74.49
- LOCO $14.10
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- LOCO 52.39
- Support Level
- NGNE $19.59
- LOCO $10.40
- Resistance Level
- NGNE $20.46
- LOCO $10.74
- Average True Range (ATR)
- NGNE 1.23
- LOCO 0.26
- MACD
- NGNE -0.20
- LOCO 0.04
- Stochastic Oscillator
- NGNE 13.37
- LOCO 75.57
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.